As shown in Table 1, opaganib increased calreticulin cell surface expression on all the cancer cells tested, with log responses ranging from 1.46 to 3.64, corresponding to ~3-fold to >400-fold increases in the pancreas, prostate, neuroblastoma, breast, lung and melanoma tumor cell lines. Here, CALR is linked to neoplasm.